Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,303.23 +56.55 (+1.08%) Dow
39,863.88 +305.77 (+0.77%) Nasdaq
16,740.94 +229.76 (+1.39%) Bitcoin USD
65,995.13 +4,426.34 (+7.19%) CMC Crypto 200
1,384.28 +116.33 (+9.17%)
KOD May 2024 5.000 put
| Previous close | 1.2300 |
| Open | 1.2300 |
| Bid | 0.9000 |
| Ask | 1.6000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.2300 - 1.2300 |
| Contract range | N/A |
| Volume | |
| Open interest | 66 |
PR NewswireKodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer.
PR NewswireKodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that nine scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, being held from May 5 – 9 in Seattle, Washington.
Simply Wall St.Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
